At the news
? BEARISHIMPACT 5/10 PRESS-RELEASE filed Aug 13, 2026 at 17:42 ET
BridgeBio announced a secondary offering of 5,000,000 shares by KKR Genetic Disorder L.P., with the company receiving no proceeds. This overhang from a large existing holder selling into a $16.4B market cap creates moderate dilution pressure, though the company's strong Q2 revenue growth and upcoming PDUFA catalysts partially offset the sentiment. The offering follows a $1B preferred equity financing and positive Q2 results, suggesting KKR is taking partial profits rather than signaling distress.
- KKR Genetic Disorder L.P. is selling 5,000,000 shares of BridgeBio common stock in a secondary public offering
- BridgeBio will not receive any proceeds from the offering
- William Blair, Goldman Sachs & Co. LLC and KKR are joint book-running managers
- The offering is being made under an automatic shelf registration statement (Form S-3ASR) filed July 24, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access